MX353154B - Emulsiones de aceite/agua que comprenden alcanos semifluorados. - Google Patents

Emulsiones de aceite/agua que comprenden alcanos semifluorados.

Info

Publication number
MX353154B
MX353154B MX2013007807A MX2013007807A MX353154B MX 353154 B MX353154 B MX 353154B MX 2013007807 A MX2013007807 A MX 2013007807A MX 2013007807 A MX2013007807 A MX 2013007807A MX 353154 B MX353154 B MX 353154B
Authority
MX
Mexico
Prior art keywords
emulsions
semi
fluorinated alkane
semifluorinated alkanes
compositions
Prior art date
Application number
MX2013007807A
Other languages
English (en)
Other versions
MX2013007807A (es
Inventor
Theisinger Bastian
Theisinger Sonja
Günther Bernhard
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2013007807A publication Critical patent/MX2013007807A/es
Publication of MX353154B publication Critical patent/MX353154B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona composiciones líquidas en la forma de emulsiones físicamente estables que comprenden un alcano semifluorado. El alcano semifluorado está comprendido en la fase dispersa, la cual puede incluir también un ingrediente farmacéutico activo. Uno de los ingredientes activos preferido es propofol. Las composiciones son, opcionalmente, esterilizables por calor y pueden usarse para aplicaciones de producto farmacéuticas o cosméticas y administrarse tópicamente, intravenosamente o vía otras rutas.
MX2013007807A 2011-01-04 2012-01-03 Emulsiones de aceite/agua que comprenden alcanos semifluorados. MX353154B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150064 2011-01-04
PCT/EP2012/050043 WO2012093113A1 (en) 2011-01-04 2012-01-03 O/w-emulsions comprising semifluorinated alkanes

Publications (2)

Publication Number Publication Date
MX2013007807A MX2013007807A (es) 2013-12-16
MX353154B true MX353154B (es) 2017-12-20

Family

ID=43978091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007807A MX353154B (es) 2011-01-04 2012-01-03 Emulsiones de aceite/agua que comprenden alcanos semifluorados.

Country Status (15)

Country Link
US (6) US20140004197A1 (es)
EP (2) EP3202421B1 (es)
JP (1) JP6073244B2 (es)
KR (1) KR101910213B1 (es)
CN (1) CN103313729B (es)
AU (1) AU2012204932B2 (es)
BR (1) BR112013016661B1 (es)
CA (1) CA2819988C (es)
DK (2) DK2661280T3 (es)
ES (2) ES2711760T3 (es)
MX (1) MX353154B (es)
PL (2) PL3202421T3 (es)
PT (2) PT2661280T (es)
TR (2) TR201808752T4 (es)
WO (1) WO2012093113A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PT2714010T (pt) 2011-05-25 2017-05-05 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
CA2862974C (en) 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CA2883003C (en) 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
GB2511028A (en) * 2012-12-18 2014-08-27 Univ Manchester Metropolitan Nano emulsions, methods of forming the same and uses thereof
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
ES2687094T3 (es) 2013-07-23 2018-10-23 Novaliq Gmbh Composiciones estabilizadas de anticuerpos
MX384877B (es) * 2014-03-03 2025-03-14 Novartis Ag Composiciones de éster de colina de ácido lipoico y métodos de uso.
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
ES2965883T3 (es) 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
JP7360452B2 (ja) 2018-09-27 2023-10-12 ダーマリック セラピューティクス， インコーポレーテッド 脂質バリアの修復
JP7292567B2 (ja) 2018-09-27 2023-06-19 ダーマリック セラピューティクス， インコーポレーテッド 局所日焼け止め製剤
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache
FR3112475B1 (fr) 2020-07-20 2023-11-10 Naos Inst Of Life Science formulation écobiologique, compatible avec la vie cellulaire, utilisable dans les domaines cosmétiques, dermopharmaceutiques ou vétérinaires
JP2024508686A (ja) * 2021-02-05 2024-02-28 エパレックス コーポレーション フォスプロポフォールの方法及び組成物
DE102021005494A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
DE102021005495A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
EP1105096B1 (en) * 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) * 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
EP1684724A4 (en) * 2003-11-19 2008-04-02 Barnes Jewish Hospital IMPROVED DRUG DELIVERY
TWI368505B (en) * 2005-05-24 2012-07-21 Wyeth Corp Versatile high load concentrate compositions for control of ecto-parasites
ES2318802T3 (es) 2005-08-05 2009-05-01 BHARAT SERUMS & VACCINES LTD. Composiciones de emulsion de propofol intravenosas que tienen eficacia conservante.
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Also Published As

Publication number Publication date
PL3202421T3 (pl) 2018-10-31
JP2014501270A (ja) 2014-01-20
CN103313729A (zh) 2013-09-18
TR201901309T4 (tr) 2019-02-21
US20230139672A1 (en) 2023-05-04
BR112013016661B1 (pt) 2021-08-03
PT2661280T (pt) 2019-02-25
US20170216204A1 (en) 2017-08-03
EP3202421A1 (en) 2017-08-09
EP3202421B1 (en) 2018-03-28
US20140004197A1 (en) 2014-01-02
CN103313729B (zh) 2016-11-09
US20250345276A1 (en) 2025-11-13
US20190224123A1 (en) 2019-07-25
MX2013007807A (es) 2013-12-16
US20200360285A1 (en) 2020-11-19
AU2012204932B2 (en) 2017-02-23
PT3202421T (pt) 2018-07-03
TR201808752T4 (tr) 2018-07-23
CA2819988A1 (en) 2012-07-12
ES2711760T3 (es) 2019-05-07
AU2012204932A1 (en) 2013-07-04
WO2012093113A1 (en) 2012-07-12
DK2661280T3 (en) 2019-03-04
EP2661280A1 (en) 2013-11-13
CA2819988C (en) 2019-11-12
BR112013016661A2 (pt) 2016-10-04
PL2661280T3 (pl) 2019-05-31
ES2675242T3 (es) 2018-07-09
JP6073244B2 (ja) 2017-02-01
DK3202421T3 (en) 2018-07-16
KR20140003477A (ko) 2014-01-09
EP2661280B1 (en) 2018-11-21
KR101910213B1 (ko) 2018-12-19

Similar Documents

Publication Publication Date Title
MX353154B (es) Emulsiones de aceite/agua que comprenden alcanos semifluorados.
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
WO2012160179A3 (en) Topical pharmaceutical composition based on semifluorinated alkanes
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
CL2016003041A1 (es) Ácidos ribonucleicos bicatenarios aislados, composiciones farmacéuticas que los comprenden y método para inhibir la expresión del gen alas1 basado en la administración de dicha composición. divisional de solicitud 2725-2014.
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
UY37098A (es) Moduladores de ror-gamma
CL2019001993A1 (es) Inhibidores selectivos de jak1.
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2016006896A (es) Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica.
CR20150629A (es) Compuestos químicos
PE20131166A1 (es) Formulacion de premezcla de dexmedetomidina
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CO2018003424A2 (es) Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma”
DOP2015000170A (es) Compuestos químicos
MX377302B (es) Composiciones para el cuidado personal con dos fases benéficas.
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
MX2018001584A (es) Composiciones de solución sólida para aines.
BR112015014367A2 (pt) formulações inibidoras de lfa-1
MX2017009482A (es) Formulación farmacéutica.

Legal Events

Date Code Title Description
FG Grant or registration